312 related articles for article (PubMed ID: 27031662)
1. The effects of cytotoxic therapy in progressive IgA nephropathy.
Shin JH; Lee JE; Park JH; Lim S; Jang HR; Kwon GY; Huh W; Jung SH; Kim YG; Oh HY; Kim DJ
Ann Med; 2016; 48(3):171-81. PubMed ID: 27031662
[TBL] [Abstract][Full Text] [Related]
2. First-year GFR slope and long-term renal outcome in IgA nephropathy.
Lee K; Shin J; Park J; Hwang S; Jang HR; Huh W; Kwon GY; Kim YG; Oh HY; Lee JE; Kim DJ
Eur J Clin Invest; 2018 Jun; 48(6):e12936. PubMed ID: 29660832
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran.
Soleymanian T; Najafi I; Salimi BH; Broomand B
Ren Fail; 2011; 33(6):572-7. PubMed ID: 21663387
[TBL] [Abstract][Full Text] [Related]
4. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Cheng G; Liu D; Margetts P; Liu L; Zhao Z; Liu Z; Tang L; Fang Y; Li H; Guo Y; Chen F; Liu F
Nephrology (Carlton); 2015 Feb; 20(2):77-84. PubMed ID: 25358874
[TBL] [Abstract][Full Text] [Related]
5. Prospective trial of combined therapy with heparin/warfarin and renin-angiotensin system inhibitors in progressive IgA nephropathy.
Ishii T; Kawamura T; Tsuboi N; Ogura M; Utsunomiya Y; Hosoya T
Contrib Nephrol; 2007; 157():114-9. PubMed ID: 17495447
[TBL] [Abstract][Full Text] [Related]
6. Progression of IgA nephropathy under current therapy regimen in a Chinese population.
Li X; Liu Y; Lv J; Shi S; Liu L; Chen Y; Zhang H
Clin J Am Soc Nephrol; 2014 Mar; 9(3):484-9. PubMed ID: 24408121
[TBL] [Abstract][Full Text] [Related]
7. Increased Serum IgA in Children with IgA Nephropathy, Severity of Kidney Biopsy Findings and Long-Term Outcomes.
Mizerska-Wasiak M; Małdyk J; Pańczyk-Tomaszewska M; Turczyn A; Cichoń-Kawa K; Rybi-Szumińska A; Wasilewska A; Firszt-Adamczyk A; Stankiewicz R; Bieniaś B; Zajączkowska M; Gadomska-Prokop K; Grenda R; Miklaszewska M; Pietrzyk J; Pukajło-Marczyk ; Zwolińska D; Szczepańska M; Demkow U; Roszkowska-Blaim M
Adv Exp Med Biol; 2015; 873():79-86. PubMed ID: 26269025
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Progression in IgA Nephropathy in Childhood.
Mizerska-Wasiak M; Małdyk J; Turczyn A; Cichoń-Kawa K; Rybi-Szumińska A; Wasilewska A; Bieniaś B; Zajączkowska M; Miklaszewska M; Pietrzyk J; Demkow U; Roszkowska-Blaim M; Pańczyk-Tomaszewska M
Adv Exp Med Biol; 2017; 955():65-73. PubMed ID: 27718216
[TBL] [Abstract][Full Text] [Related]
9. The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy.
Tanaka S; Ninomiya T; Katafuchi R; Masutani K; Nagata M; Tsuchimoto A; Hirakata H; Kitazono T; Tsuruya K
Clin Exp Nephrol; 2016 Oct; 20(5):689-698. PubMed ID: 26564155
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
Manno C; Torres DD; Rossini M; Pesce F; Schena FP
Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy.
Rasche FM; Klotz CH; Czock D; Karges W; Muche R; Jehle PM; Mertz A; Keller F
Nephron Clin Pract; 2003; 93(4):c131-6. PubMed ID: 12759581
[TBL] [Abstract][Full Text] [Related]
12. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
Li S; Li JP
Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
[TBL] [Abstract][Full Text] [Related]
13. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol.
Eitner F; Ackermann D; Hilgers RD; Floege J
J Nephrol; 2008; 21(3):284-9. PubMed ID: 18587715
[TBL] [Abstract][Full Text] [Related]
14. [Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].
Pozzi C; Del Vecchio L; Locatelli F
G Ital Nefrol; 2002; 19(5):523-8. PubMed ID: 12439840
[TBL] [Abstract][Full Text] [Related]
15. Treatment of IgA nephropathy.
Pozzi C
J Nephrol; 2016 Feb; 29(1):21-5. PubMed ID: 26577268
[TBL] [Abstract][Full Text] [Related]
16. Primary IgA nephropathy in elderly patients.
Cheungpasitporn W; Nasr SH; Thongprayoon C; Mao MA; Qian Q
Nephrology (Carlton); 2015 Jun; 20(6):419-25. PubMed ID: 25726845
[TBL] [Abstract][Full Text] [Related]
17. Treatment of severe Henoch-Schönlein and immunoglobulin A nephritis. A single center experience.
Edström Halling S; Söderberg MP; Berg UB
Pediatr Nephrol; 2009 Jan; 24(1):91-7. PubMed ID: 18931859
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.
Hogg RJ; Bay RC; Jennette JC; Sibley R; Kumar S; Fervenza FC; Appel G; Cattran D; Fischer D; Hurley RM; Cerda J; Carter B; Jung B; Hernandez G; Gipson D; Wyatt RJ
Am J Kidney Dis; 2015 Nov; 66(5):783-91. PubMed ID: 26209543
[TBL] [Abstract][Full Text] [Related]
19. Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function.
Moriyama T; Amamiya N; Ochi A; Tsuruta Y; Shimizu A; Kojima C; Itabashi M; Takei T; Uchida K; Nitta K
Clin Exp Nephrol; 2011 Oct; 15(5):700-707. PubMed ID: 21625892
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive therapy in patients with IgA nephropathy.
Peters HP; van den Brand JA; Berger SP; Wetzels JF
Neth J Med; 2015 Jul; 73(6):284-9. PubMed ID: 26228193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
